Identifying genetic predictors of durable clinical benefit to pembrolizumab in advanced non-small cell lung cancer alone and in combination with chemotherapy.
A study to identify the benefits of study drug pembrolizumab in patients with advanced or recurrent cancers
Sponsor: Merck
Enrolling: Male and Female Patients
IRB Number: AAAQ5450
U.S. Govt. ID: NCT02710396
Contact: Naiyer Rizvi: 646-317-6344 / nar2144@cumc.columbia.edu
Additional Study Information: This is a research study to test the effectiveness of pembrolizumab on cancer types having a known relationship to smoking carcinogen exposure. The study will enroll 120 subjects age 18 and above with advanced solid tumor related to smoking exposure. All patients will receive the treatment of pembrolizumab. The study aims to determine if tumor genetics can predict the effect of pembrolizumab on non-small-cell lung carcinoma.
This study is closed
Investigator
Do You Qualify?
Have you been diagnosed with an advanced solid tumor related to smoking? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Naiyer Rizvi
nar2144@cumc.columbia.edu
646-317-6344
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE